Price Disclosure (SPD)

Page last updated: 1 December 2016

Outcomes from Price Disclosure (SPD)

Indicative Prices - Disclosure Cycles

The spreadsheets attached below set out indicative price disclosure related price changes effective on the specified reduction day.  Medicines in the cycle that are not taking a reduction are not included in the spreadsheet.  The spreadsheets include:

  • legal brand of pharmaceutical item taking a reduction – this is the formal product description in the PBS listing instrument;
  • ex-manufacturer prices - Approved Ex-Manufacturer Price (AEMP) for pricing quantity and the Proportional Ex-Manufacturer Price (PEMP) where pack size is different to pricing quantity.  This is the price without fees and mark-ups;
  • Price to Pharmacy (PTP) for pack size - this price can also be worked out for an individual product by adding the wholesaler mark-up where applicable;
  • Dispensed Price for Maximum Quantity (DPMQ) – dispensed price for supply through community pharmacy, or under s100 arrangement or other specified program. The Dispensed Price for Maximum Amount (DPMA) is given for Efficient Funding of Chemotherapy injectibles;
  • manufacturer’s claimed prices and resulting premium – only included for medicines with a premium / other special patient contribution. The method for calculating a premium / other special patient contribution is set out in the National Health Act 1953 (the Act) and described at paragraph 121 on page 35 of the Price Disclosure Procedural and Operational Guidelines;
  • Trade Product Pack (TPP) - an Australian Medicines Terminology (AMT) description. AMT is used in the Schedule of Pharmaceutical Benefits.

These indicative price disclosure related price changes are being made available in advance of the effective date to assist companies and other stakeholders. They will come into effect under the Act and the National Health (Pharmaceutical Benefits) Regulations 1960 and have already been announced publicly - see 'Outcomes from Price Disclosure (SPD)'.

Confirmation of New Prices – Disclosure Cycles

The spreadsheets below set out price disclosure related price changes effective on the reduction day mentioned.  This includes all the levels of PBS prices previously published under the Indicative Prices heading above.

These price disclosure related changes are being made available in advance of the effective date to assist companies.  They come into effect under the National Health Act 1953 and have already been announced publicly (refer to Outcomes from Price Disclosure section above).

Reference documents

Primary Sources

Explanatory Materials